These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28405509)

  • 1. Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab.
    Skrepnik T; Sundararajan S; Cui H; Stea B
    Oncoimmunology; 2017; 6(3):e1283461. PubMed ID: 28405509
    [No Abstract]   [Full Text] [Related]  

  • 2. Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.
    Burke AM; Carrasquilla M; Jean WC; Collins BT; Anaizi AN; Atkins MB; Gibney GT; Collins SP
    Front Oncol; 2021; 11():794615. PubMed ID: 35096594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
    Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
    J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
    J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
    Jablonska PA; Muniz T; Ribeiro M; Liu ZA; Ye XY; Devaraja K; Laperriere N; Millar BA; Conrad T; Kongkham P; Butler M; Shultz DB
    J Neurooncol; 2023 Aug; 164(1):199-209. PubMed ID: 37552363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
    Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
    Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective.
    Liermann J; Winkler JK; Syed M; Neuberger U; Reuss D; Harrabi S; Naumann P; Ristau J; Weykamp F; El Shafie RA; König L; Debus J; Hassel J; Rieken S
    Front Oncol; 2020; 10():592796. PubMed ID: 33178618
    [No Abstract]   [Full Text] [Related]  

  • 15. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
    Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
    Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis.
    Bodensohn R; Werner S; Reis J; Pazos Escudero M; Kaempfel AL; Hadi I; Forbrig R; Manapov F; Corradini S; Belka C; Theurich S; Heinzerling L; Schlaak M; Niyazi M
    Clin Transl Radiat Oncol; 2023 Mar; 39():100573. PubMed ID: 36655118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
    Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy.
    Andring L; Squires B; Seymour Z; Fahim D; Jacob J; Ye H; Marvin K; Grills I
    Int J Neurosci; 2023 Feb; 133(2):186-193. PubMed ID: 33685315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.
    An Y; Jiang W; Kim BYS; Qian JM; Tang C; Fang P; Logan J; D'Souza NM; Haydu LE; Wang XA; Hess KR; Kluger H; Glitza IC; Mahajan A; Welsh JW; Lin SH; Yu JB; Davies MA; Hwu P; Sulman EP; Brown PD; Chiang VLS; Li J
    Radiother Oncol; 2017 Oct; 125(1):80-88. PubMed ID: 28916225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.